FDA allows Philip Morris to market Zyn as less harmful than cigarettes
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/7/2026
- Wall Street ends lower as solid jobs data fuels hawkish Fed bets
- US nonfarm payrolls blow past expectations in August; unemployment rate steady at 4.1%
- BofA's Hartnett says stay long commodities and gold as 'policy panic' works
- Oil ends week higher on renewed US-Iran strikes, diesel hits record
- TikTok owner ByteDance said to secure $29.6bn loan for AI push
- After-Hours Movers: LULU, IOT, PATH, DOCU, ASAN, GWRE, ZS, PL, SWBI, OXM
- After-Hours Movers: AVGO, SNOW, HPE, NTAP, NTSK, CHPT, FIVE, TLYS, PVH, RARE
- After-Hours Movers: DELL, PANW, GTLB, CRDO, MDB, HPE, SMCI
- After-Hours Movers: WDAY, ADSK, S, RBRK, MRVL, ULTA, GAP, AFRM
- After-Hours Movers: NVDA, CRM, SNPS, CRWD, OKTA, NTNX
BofA on Philip Morris (PM): 'one of the best positioned companies in the consumer staples sector'
June 30, 2026 1:09 PM EDTBofA Securities analyst Lisa Lewandowski reiterated a Buy rating and $209.00 price target on Philip Morris (NYSE: PM).
The analyst comments "MRTP orders are important because the applications undergo strict, science-based testing for any tobacco product that claims to be less harmful than others. Before a manufacturer can market a product with reduced-risk or reduced-exposure claims, it must obtain an... More
